Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etynodiol is a synthetic progestin (progestogen) used as a component of oral contraceptives. It acts as an agonist of the progesterone receptor and has weak androgenic and estrogenic activity. Etynodiol itself is not marketed alone but is available in the form of its diacetate ester (etynodiol diacetate), which serves as a prodrug that is rapidly converted in the body to norethisterone via etynodiol as an intermediate. Its primary mechanism involves binding to progesterone receptors, suppressing ovulation by inhibiting gonadotropin release from the hypothalamus and pituitary gland, altering cervical mucus to impede sperm penetration, and modifying endometrial lining to prevent implantation[5][7]. Etynodiol was discovered in 1954.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etynodiol.